Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Synta Pharmaceuticals logo — Innovating patient care with advanced small molecule therapi...

Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, including cancer and chronic inflammatory diseases.

Founded 2000 Post Ipo Equity Total: $217.35M Biotechnology, Health Care +1

General Information

Company Name Synta Pharmaceuticals
Founded Year 2000
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Synta Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Synta Pharmaceuticals

Synta Pharmaceuticals is a biopharmaceutical company founded in 2000, with a focus on discovering, developing, and commercializing small molecule drugs to improve the lives of patients with severe medical conditions such as cancer and chronic inflammatory diseases. The company has a global partnership with Roche for the development of novel CRACM inhibitors, and various drug candidates and programs in its portfolio. These include STA-9090, elesclomol, and apilimod, each targeting different medical conditions in various developmental stages. In April 2015, the company secured a $38.50M post-IPO equity investment. With its strong track record and focus on addressing critical medical needs, Synta Pharmaceuticals is a noteworthy player in the fields of Biotechnology, Health Care, and Pharmaceuticals. Based in Lexington, Massachusetts, the company continues to make strides in advancing patient care through its innovative small molecule therapies.

Taxonomy: biopharmaceutical company, small molecule drugs, cancer treatment, chronic inflammatory diseases, drug discovery, clinical development, global partnership, Roche collaboration, lead optimization, autoimmune diseases, Hsp90 inhibitor, rheumatoid arthritis, medical innovations

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 01 Apr 2015
Post-IPO Equity •••••• - 19 Jan 2010
Post-IPO Equity •••••• - 08 Jan 2010
Venture Round •••••• - 22 Oct 2006
Series D •••••• - 07 Dec 2004

View All 8 Funding Rounds

Synta Pharmaceuticals Alternatives & Competitors

Synta Pharmaceuticals vs
MethylGene
MethylGene

Harnessing Innovation to Develop Next-Generation Cancer Therapies

Series Unknown
Biopharma, Biotechnology
Synta Pharmaceuticals vs
Ayala Pharmaceuticals
Ayala Pharmaceuticals United States

Clinical-stage oncology company focused on developing and commercializing small molecule therapeutic...

Post Ipo Equity
30 employees
Biotechnology, Pharmaceutical
Synta Pharmaceuticals vs
Raptor Pharmaceuticals
Raptor Pharmaceuticals

Embarking on a journey to better health through innovative biotechnology solutions for brain, geneti...

Post Ipo Equity
Biopharma, Biotechnology

FAQ About Synta Pharmaceuticals

Innovating patient care with advanced small molecule therapies for severe medical conditions, including cancer and chronic inflammatory diseases.
Synta Pharmaceuticals was founded in 2000.
Synta Pharmaceuticals operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Synta Pharmaceuticals has completed 8 funding rounds, raising a total of $217.35M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Synta Pharmaceuticals include MethylGene, Ayala Pharmaceuticals , Raptor Pharmaceuticals, Oryzon Genomics SA, Aviragen Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Synta Pharmaceuticals and MethylGene are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Synta Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy